ArticleCJC open2026
An Analysis of Patient Recovery and Opinions on Driving Post-Transcatheter Aortic Valve Insertion (TAVI): the TAVI-D Study.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter aortic valve insertion (TAVI) is heralded for being minimally invasive and requiring shorter recovery, compared to surgical aortic valve replacement. In 2023, the Canadian Cardiovascular Society published guidelines recommending a 1-month driving (noncommercial drivers) restriction for both procedures. A 2024 Canadian physician survey study showed overwhelming support for a shorter TAVI guideline. Methods: An observational prospective assessment of TAVI patient recovery was conducted from June 2024 to January 2025 at the Mazankowski Alberta Heart Institute. Post-TAVI patients were followed clinically and completed a 17-question survey examining symptoms, clinical events, and opinions on driving. Results: Of 111 participants, 96.4% received transfemoral (TF) TAVI. Of patients requiring pacemaker insertion (n = 20), 95% were symptomatic within 1 week of their procedure (1 was symptomatic at 2 weeks). A total of 65% of pacemaker-requiring patients (n = 13 of 20) were implanted during TAVI admission. Readmission for pacemaker insertion (n = 7) occurred in 71.4% (n = 5) within 2 weeks and 28.6% (n = 2) after 3 weeks, a calculated population on-the-road risk of harm of 0.0014%. A total of 90% of pacemaker patients had pre- and/or post-TAVI conduction abnormalities. Two patients developed atrial fibrillation and new right bundle branch block requiring pacemaker insertion at, respectively, 4 and 7 days post-TAVI-a 0.0004% risk. A total of 52.3% expressed that a 1-month driving restriction was "too long." Conclusions: With calculated population on-the-road risks of harm well below the established Canadian Cardiovascular Society threshold of 0.005% (1 of 20,000), we propose shortening noncommercial driving restrictions, to 48 hours for patients with successful uncomplicated transfemoral TAVI without conduction disturbances, and to 2 weeks for those with asymptomatic conduction abnormalities who do not receive a pacemaker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.